https://www.bioworld.com/rss en-us Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis. http://www.bioworld.com/articles/732324 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732324-hexapharmatec-identifies-new-tfeb-inducers Merck Sharp & Dohme LLC (MSD) has synthesized new protein zer-1 homolog (Hzyg, ZER1) ligands potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732323 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732323-hzyg-ligands-disclosed-in-msd-patent Yaoya Technology (Shanghai) Co. Ltd. has discovered new pyrimidothiopyrandione GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732322 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732322-yaoya-technology-identifies-new-kras-g12d-mutant-inhibitors Blueprint Medicines Corp. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732321 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732321-blueprint-medicines-reports-new-cdk4-degrader-protacs Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new Kelch-like ECH-associated protein 1 (KEAP1) activators and nuclear factor erythroid 2-related factor 2 (NRF2) degradation inducers potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732320 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732320-sichuan-kelun-biotech-discloses-new-keap1-activators-and-nrf2-degradation-inducers Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and selectively activates human GHR for the treatment of GH deficiency (GHD). It is designed to enable once-every-4-week dosing. http://www.bioworld.com/articles/732314 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732314-gensci-134-a-long-acting-growth-hormone-receptor-agonist-fusion-protein 3D illustration of human growth hormone molecules Human growth hormone. A Biotech Co. Ltd., a subsidiary of CDW Holding Ltd., and Neoregen Biotech Co. Ltd. have obtained promising results from in vivo murine testing of LNP-LANFA, a next-generation lipid nanoparticle (LNP) technology under joint development. http://www.bioworld.com/articles/732313 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732313-cdw-reports-in-vivo-results-for-lnp-lanfa 3D concept image of nanoparticle layers Spinal cord traumatic injury can lead to loss of motor function and progressive development of muscle spasticity and rigidity. Researchers from the University of California San Diego and collaborating institutions investigated a novel gene-delivery-based antispasticity strategy. http://www.bioworld.com/articles/732312 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732312-preclinical-study-of-subpial-aav-gad65-vgat-delivery-for-spinal-injury-induced-spasticity Digital spine concept art Smartbax GmbH has announced the successful second closing of its pre-series A financing round for a total of €6.3 million (US$7.2 million) as it advances development of next-generation antibiotics against multidrug-resistant bacteria. http://www.bioworld.com/articles/732311 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732311-smartbax-raises-additional-funds-to-advance-antibiotic-pipeline Illustration of medical professionals, research A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal. http://www.bioworld.com/articles/732310 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732310-deerfield-backed-boulevard-metis-pen-16b-trispecific-tce-deal Handshake, businessmen holding dollar sign, lightbulb Predominantly expressed in the striatum, a brain region involved in cognition, motivation and motor control, G protein-coupled receptor 52 (GPR52) regulates dopaminergic and glutamatergic signaling pathways implicated in psychiatric disorders. http://www.bioworld.com/articles/732309 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732309-novel-gpr52-agonist-shows-antipsychotic-like-effects It is known that bacterial cells exchange biological matter, but it is not clear whether bacteria can exchange functional proteins. In a recent paper published in Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment. Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment.]]> http://www.bioworld.com/articles/732308 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732308-antibiotics-spur-protein-transfer-that-boosts-bacterial-survival Petri dish and capsules lynn.yoffee@clarivate.com Awards are an honor, but they are not why we do what we do. That's why this year's recognition from the APEX Awards is especially meaningful. BioWorld earned seven 2026 APEX Awards, including three Grand Awards and four Awards of Excellence. Judged by publishing industry peers, these honors recognize excellence across reporting, writing, visual storytelling and editorial collaboration. While we are proud of this recognition, what makes it especially rewarding is that it reflects the work our team does every day to serve the global life sciences community. 2026 APEX Awards, including three Grand Awards and four Awards of Excellence. Judged by publishing industry peers, these honors recognize excellence across reporting, writing, visual storytelling and editorial collaboration. While we are proud of this recognition, what makes it especially rewarding is that it reflects the work our team does every day to serve the global life sciences community.]]> http://www.bioworld.com/articles/732328 Tue, 30 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/732328-celebrating-recognition-reaffirming-our-mission Award ribbon icon Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported new CDK4/cyclin D1 inhibitors potentially useful for the treatment of breast cancer. http://www.bioworld.com/articles/732220 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732220-shandong-simcere-medgenn-bio-pharmaceutical-divulges-new-cdk4-cyclin-d1-inhibitors Beijing Earthwise Technology Co. Ltd. has patented new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 ligase/proto-oncogene Vav (VAV1) interaction inducers and VAV1 degradation inducers. http://www.bioworld.com/articles/732219 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732219-beijing-earthwise-technology-discovers-new-e3-ligase-vav1-interaction-inducers Boyuan Pharmaceutical (Suzhou) Co. Ltd. has divulged new pyridone derivatives potentially useful for the treatment of HIV infection. http://www.bioworld.com/articles/732218 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732218-anti-hiv-compounds-reported-in-boyuan-pharmaceutical-patent Jiangxi Kerui Pharmaceutical Co. Ltd. has disclosed new prodrugs of fungal GPI-anchored wall transfer protein 1 (GWT1) inhibitors potentially useful for the treatment of fungal infections. http://www.bioworld.com/articles/732217 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732217-jiangxi-kerui-pharmaceutical-patents-new-fungal-gwt1-inhibitors Changchun Genescience Pharmaceuticals Co. Ltd. has synthesized new molecular glue degraders comprising E3 ubiquitin-protein ligase-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are described as potentially useful for the treatment of ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis. http://www.bioworld.com/articles/732216 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732216-changchun-genescience-pharmaceuticals-discloses-new-vav1-degradation-inducers Genescience Pharmaceuticals Co. Ltd. has been developing an SLC6A19 inhibitor – Gensci-144 – for the potential treatment of chronic kidney disease (CKD). http://www.bioworld.com/articles/732211 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732211-gensci-144-shows-renoprotection-in-ckd Illustration of diseased kidney Prostate cancer is a leading cause of cancer-related deaths among men and is a cancer type that shows genomic heterogeneity and several molecular alterations. By analyzing available microarray and next-generation transcriptome sequencing data, researchers at the University of Alabama at Birmingham found that thyroid hormone receptor-interacting protein 13 (TRIP13), a member of the AAA ATPase family, was overexpressed in prostate cancer, making it a potential therapeutic target. http://www.bioworld.com/articles/732210 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732210-trip13-blockade-as-a-therapeutic-approach-in-prostate-cancer 3D illustration showing tumor inside prostate gland and closeup view of cancer cells Neurodegenerative disorders such as Alzheimer’s disease (AD) and frontotemporal dementia are characterized by the accumulation of hyperphosphorylated tau protein, forming neurofibrillary tangles, ultimately leading to synaptic dysfunction and cognitive decline. http://www.bioworld.com/articles/732209 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732209-ext1-targeted-aav-gene-therapy-inhibits-tau-propagation-in-model-of-tauopathy Silhouette of head and brain with DNA double helixes Credit: Jonathan Bailey, NHGR Chronic activation or upregulation of interleukin-1 receptor-associated kinase 4 (IRAK4) has been linked to several diseases, including systemic lupus erythematosus, rheumatoid arthritis, atopic dermatitis, Alzheimer’s disease and atherosclerosis. Researchers from the Ocean University of China aimed to address the limitations of traditional small-molecule inhibitors by designing novel proteolysis targeting chimeras (PROTACs) for IRAK4 degradation. http://www.bioworld.com/articles/732208 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732208-irak4-targeting-protac-degrader-suppresses-inflammatory-signaling-in-vitro 3D rendering of interleukin-1 receptor-associated kinase 4 IRAK4, a protein kinase involved in signaling innate immune responses from Toll-like receptors. ALK5 mediates the core profibrotic TGF-β signaling cascade that promotes fibroblast activation, myofibroblast differentiation and extracellular matrix production, ultimately leading to persistent tissue remodeling and lung fibrosis. http://www.bioworld.com/articles/732207 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732207-inhaled-alk5-inhibitor-delivers-lung-targeted-antifibrotic-effects Digital lungs illustration Onco-Innovations Ltd. has announced the initiation of hepatocyte and liver microsome metabolism studies for ONC-010, the company’s lead nanoparticle-formulated PNKP inhibitor. The studies will evaluate the metabolic stability of ONC-010 across human, rat and dog systems. http://www.bioworld.com/articles/732206 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732206-onco-innovations-evaluates-onc-010-in-metabolism-studies Illustration of human body composed of molecules Up to 90% of people with dementia develop at least one behavioral or psychological symptom, such as psychosis, anxiety or agitation/aggression, which often overlap and worsen both patient quality of life and caregiver burden. Based on preclinical evidence, dual 5-HT2A/7 receptor antagonism may represent a rational strategy to modulate psychosis, agitation and mood-related symptoms. http://www.bioworld.com/articles/732205 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732205-sumitomos-dual-5-ht2a-7-receptor-antagonist-counteracts-dementia-symptoms The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732204 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732204-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic. http://www.bioworld.com/articles/732274 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732274-oblenios-62m-series-b-for-trispecific-antibody-in-autoimmune-diseases Antibodies illustration Laekna Pharmaceutical Ningbo Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors found to be potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732201 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732201-new-wrn-inhibitors-reported-in-laekna-pharmaceutical-patent Researchers from Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase (such as Von Hippel-Lindau disease tumor suppressor [VHL]) coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732200 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732200-ascentage-describes-new-bcl-xl-degradation-inducers Shanghai Yingli Pharmaceutical Co. Ltd. has discovered hydrazine-structured compounds as inhibitors of GTPase KRAS and its mutants. They are reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732199 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732199-shanghai-yingli-pharmaceutical-identifies-new-kras-mutant-inhibitors